Allison Bratzel

“So I think, you know, you talked about the number of institutions you have prescribed future keV. Could you talk to maybe how many have actually administered a dose, and what is the typical time from prescription to first injection?”

“Just, you know, following up on the stereochemistry data and the single nucleotide initiation capabilities you guys showed at Tides USA, could you just talk more to, you know, what has customer reaction actually looked like since then?”

“One from me on 635, could you just talk to your expectations for the placebo arm in the phase two? Are the small molecule trials a good benchmark of what to expect from the placebo?”

“One question for me, just on 635, I know you've talked about encouraging target engagement data and how that's increased your probability of success in VMS. Could you just expand on that, you know, will that data be presented or published or can we expect to see it in Q3 with the data readout?”

“Maybe just a quick one going back to citruzumab. I think you previously discussed a hypothesis that Orbit missed. because treated patients felt better, became more active, and thus more likely to fracture.”